Chemotherapy and radiation have been cancer treatments since the 1950s, and in the meantime, science has developed more than 200 drugs to fight cancer.
All these established treatments have one thing in common. They're all more or less "one size fits all" treatments, procedures, or regimens.
But out on the frontier of cancer research where, as I've said, the most exciting, promising discoveries (and biggest profits) are made, there's a treatment under development that's going to disrupt the field for the next several decades.
I'm talking about powerful "bespoke" cancer treatments for every patient, using their own bodies to boot.
Not only will this improve and save lives, it'll also crack open a market worth $25 billion by 2025. It really is a revolutionary development.
But the "Buy" call I'm making today is still trading at "pre-revolutionary" prices…
The "A-Bomb" in the Cancer Fight
I can't overstate this. The treatment I'm going to tell you about, as well as the most important company pioneering it, will change cancer treatment the way the atomic bomb changed the face of warfare moving forward.
This biotech "A-bomb" is called immunotherapy, or "IO" to insiders. And it's progressing rapidly.
The technique is straight out of science fiction. Immunotherapy uses a patient's own immune system – "tweaking" it by either suppressing, stimulating, or enhancing an immune response – to effect a desired change. It can be used to vaccinate people and fight microbial diseases, reduce allergic reactions, suppress the sometimes devastating response to organ transplants, and, most promisingly, help patients destroy their own tumors and beat cancer.
Right now there are over 1,000 drug trials underway for IO candidates. The trials are mainly involving patients whose cancer isn't responding to traditional therapies like chemo or radiation and who are now terminal.
There's good reason to move with haste. The longer we live, the more likely we are to develop some form of cancer. It's always been a killer, but it's becoming a huge problem.
In addition to the human cost, treatments are now running about $10,000 a month, according to U.S. News & World Report. Insurers, doctors, researchers, regulators, and patients are all on the same page here. That's been an important driver in IO's development.
I'm bullish on this entire segment, and I'm not alone. Barclays is expecting IO to be worth $25 billion by 2025 – just eight years.
Now let me show you the company I think will reap the most benefit from this "frontier" research drive and incredible momentum.
This Small Company Is at the Top of the Pyramid
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top technology financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
Michael is 100% independent and receives absolutely no compensation from companies he writes about. His ideas are completely his own.
So, it probably goes without saying that you won't ever be left in the dark about breaking innovations, ahead-of-their-time technologies, and breakout companies on the cusp of changing the world once you join this world.